Passage Bio Inc., a biotechnology company, has presented its latest corporate update, focusing on advancements in the treatment of neurodegenerative diseases. The presentation highlights the development of PBFT02, a gene therapy aimed at raising progranulin levels for conditions such as Frontotemporal Dementia (FTD) caused by GRN mutations. The company has established a suspension-based manufacturing process to support the late-stage development of this therapy. Passage Bio expects its cash reserves to sustain operations until the end of the first quarter of 2027. The upcoming milestones include reporting updated interim safety and biomarker data from Dose 2 in the second half of 2025 and seeking regulatory feedback on their manufacturing process and trial design in the first half of 2026. The presentation underscores the significant market opportunity for PBFT02 across various neurodegenerative disorders, including ALS and Alzheimer's Disease. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。